Literature DB >> 2883815

Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia.

H A Youssef, J L Waddington.   

Abstract

A population of 101 chronic schizophrenic inpatients were assessed for the presence or absence of tardive dyskinesia, and followed up 32 months later. At follow up, the mortality rates in 44 patients with and 57 patients without involuntary movements were 16% vs. 9% respectively; this difference widened when only the more prominent involuntary movements were considered. Of those surviving, patients with tardive dyskinesia were much more likely to contract an attack of respiratory tract infection, and to do so on multiple occasions, and tended to suffer from more cardiovascular disorders. They appeared more likely to show smoking-related pathology. Chronic schizophrenic patients with tardive dyskinesia constitute a more biologically disadvantaged group, suggesting a broader disease concept of the syndrome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883815     DOI: 10.1111/j.1600-0447.1987.tb02754.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  9 in total

1.  Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study.

Authors:  Itzhak Kimiagar; Evgenia Dobronevsky; Tatiana Prokhorov; Ala Miniovitz; Jose M Rabey
Journal:  J Neurol       Date:  2011-11-09       Impact factor: 4.849

2.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 3.  Movement disorders: neurodevelopment and neurobehavioural expression.

Authors:  T Archer; R J Beninger
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

4.  Movement Disorders and Mortality in Severely Mentally Ill Patients: The Curacao Extrapyramidal Syndromes Study XIV.

Authors:  Anne E Willems; Charlotte L Mentzel; Pieter Roberto Bakker; Jim Van Os; Diederik E Tenback; Petra Gelan; Erna Daantjes; Glenn E Matroos; Hans W Hoek; Peter N Van Harten
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

5.  Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia.

Authors:  Xiang Yang Zhang; Da Chun Chen; Ling Yan Qi; Fang Wang; Mei Hong Xiu; Song Chen; Gui Ying Wu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

6.  Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy.

Authors:  Shaina Musco; Laura Ruekert; Jaclyn Myers; Dennis Anderson; Michael Welling; Elizabeth Ann Cunningham
Journal:  J Clin Psychopharmacol       Date:  2019 Jul/Aug       Impact factor: 3.153

7.  Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study.

Authors:  Rikinkumar S Patel; Zeeshan Mansuri; Amit Chopra
Journal:  Heliyon       Date:  2019-05-17

8.  Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia.

Authors:  Joseph McEvoy; Sanjay K Gandhi; Avery A Rizio; Stephen Maher; Mark Kosinski; Jakob Bue Bjorner; Benjamin Carroll
Journal:  Qual Life Res       Date:  2019-08-21       Impact factor: 4.147

9.  Globus Pallidus Internus Deep Brain Stimulation for Dystonic Opisthotonus in Adult-Onset Dystonia: A Personalized Approach.

Authors:  Kantharuby Tambirajoo; Luciano Furlanetti; Michael Samuel; Keyoumars Ashkan
Journal:  Front Hum Neurosci       Date:  2021-06-10       Impact factor: 3.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.